Advertisement

Pediatric Drugs

, Volume 19, Issue 3, pp 173–181 | Cite as

Hepatitis B During Pregnancy in Endemic Areas: Screening, Treatment, and Prevention of Mother-to-Child Transmission

  • Naichaya Chamroonkul
  • Teerha PiratvisuthEmail author
Therapy in Practice

Abstract

The proper management of pregnant women infected with hepatitis B virus (HBV) is necessary to prevent maternal and fetal morbidity and mortality and to protect the baby from HBV infection. In the majority of cases, vertical transmission can be prevented with a universal screening program, HBV vaccine immunoprophylaxis, and administration of hepatitis B immunoglobulin (HBIg) for babies born to mothers with HBV. However, in mothers with a high viral load (>200,000 or >1,000,000 IU/ml, depending on the guideline), the chance of immunoprophylaxis failure remains high. The standard recommendation is to give an antiviral agent during the third trimester in these patients. US FDA pregnancy category B agents such as tenofovir and telbivudine are allowed through all trimesters of pregnancy. Breastfeeding for patients who receive antiviral agents can be allowed after a risk–benefit discussion with the patient.

Keywords

Lamivudine Tenofovir Telbivudine MTCT Prophylaxis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with Ethical Standards

Conflict of interest

Naichaya Chamroonkul has no conflicts of interest. Teerha Piratvisuth has received research grants from Geliad, MSD, and BMS and consulting fees or speakers’ honoraria from Geliad, MSD, BMS, Roche, GSK, Novatis, and Bayers.

Funding

No sources of funding were used to support the writing of this manuscript.

References

  1. 1.
    GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.CrossRefGoogle Scholar
  2. 2.
    World Health Organization. Hepatitis B fact sheet. Geneva: WHO. 2016. http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 15 July 2016.
  3. 3.
    Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol. 2005;34(Suppl. 1):S1–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Jonas MM. Hepatitis B and pregnancy: an underestimated issue. Liver Int. 2009;29(Suppl. 1):133–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292:771–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Chang MH. Natural history of hepatitis B virus infection in children. J Gastroenterol Hepatol. 2000;15:E16–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology. 1987;92:1844–50.CrossRefPubMedGoogle Scholar
  9. 9.
    McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151:599–603.CrossRefPubMedGoogle Scholar
  10. 10.
    Kao JH. Hepatitis B vaccination and prevention of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2015;29(6):907–17.CrossRefPubMedGoogle Scholar
  11. 11.
    Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101:1348–55.CrossRefPubMedGoogle Scholar
  12. 12.
    Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.CrossRefPubMedGoogle Scholar
  13. 13.
    European Association for the Study of the Liver, et al. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85.CrossRefGoogle Scholar
  14. 14.
    Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.CrossRefPubMedGoogle Scholar
  15. 15.
    Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology. 1987;7(2):302–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Pirutvisuth T. Optimal management of HBV infection during pregnancy. Liver Int. 2013;33(1):188–94.CrossRefGoogle Scholar
  17. 17.
    Pan CQ, Lee HM. Antiviral therapy for chronic hepatitis B in pregnancy. Semin Liver Dis. 2013;33(2):138–46.CrossRefPubMedGoogle Scholar
  18. 18.
    Sirilert S, Traisrisilp K, Sirivatanapa P, Tongsong T. Pregnancy outcomes among chronic carriers of hepatitis B virus. Int J Gynaecol Obstet. 2014;126(2):106–10.CrossRefPubMedGoogle Scholar
  19. 19.
    Tan J, Surti B, Saab S. Pregnancy and cirrhosis. Liver Transpl. 2008;14:1081–91.CrossRefPubMedGoogle Scholar
  20. 20.
    Shaheen AAM, Myers RP. The outcomes of pregnancy in patients with cirrhosis: a population-based study. Liver Int. 2010;30:275–83.CrossRefPubMedGoogle Scholar
  21. 21.
    Russell MA, Craigo SD. Cirrhosis and portal hypertension in pregnancy. Semin Perinatol. 1998;22:156–65.CrossRefPubMedGoogle Scholar
  22. 22.
    Britton RC. Pregnancy and esophageal varices. Am J Surg. 1982;143:421–5.CrossRefPubMedGoogle Scholar
  23. 23.
    ter Borg MJ, Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat. 2008;15:37–41.PubMedGoogle Scholar
  24. 24.
    Lin HH, Chen PJ, Chen DS, Sung JL, Yang KH, Young YC, et al. Postpartum subsidence of hepatitis B viral replication in HBeAg-positive carrier mothers. J Med Virol. 1989;29:1–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Dyson JK, Waller J, Turley A, Michael E, Moses S, Valappil M, et al. Hepatitis B in pregnancy. Frontline Gastroenterol. 2014;5:111–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Giles M, Visvanathan K, Lewin S, Bowden S, Locarnini S, Spelman T, et al. Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B. Gut. 2015;64:1810–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Tan HH, Lui HF, Chow WC. Chronic hepatitis B virus (HBV) infection in pregnancy. Hepatol Int. 2008;2:370.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Nguyen V, Tan PK, Greenup AJ, Glass A, Davison S, Samarasinghe D, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment Pharmacol Ther. 2014;39:1225–34.CrossRefPubMedGoogle Scholar
  29. 29.
    Chang CY, Aziz N, Poongkunran M, Javaid A, Trinh HN, Lau D, Nguyen MH. Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B. Am J Gastroenterol. 2016;111(10):1410–5.CrossRefPubMedGoogle Scholar
  30. 30.
    He T, Jia J. Chronic HBV: which pregnant women should be treated? Liver Int. 2016;36(Suppl. S1):105–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Patton H, Tran TT. Management of hepatitis B during pregnancy. Nat Rev Gastroenterol Hepatol. 2014;11:402–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Antiretroviral Pregnancy Registry Steering Committee. The Antiretroviral Pregnancy Registry interim report. 1 January 1989 through 31 January 2016. http://www.apregistry.com/forms/interim_report.pdf. Accessed 26 Nov 2016.
  33. 33.
    DegliEsposti S, Shah D. Hepatitis B in pregnancy: challenges and treatment. Gastroenterol Clin North Am. 2011;40:355–72.CrossRefGoogle Scholar
  34. 34.
    Pan CQ, Duan ZP, Bhamidimarri KR, Zou HB, Liang XF, Li J, et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2012;10(5):452–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009;190:489–92.PubMedGoogle Scholar
  36. 36.
    Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HbsAg positive mothers. J Viral Hepat. 2012;19:e18–25.CrossRefPubMedGoogle Scholar
  37. 37.
    Xu DZ, Yan YP, Choi BC, Xu JQ, Men K, Zhang JX, et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case–control study. J Med Virol. 2002;67:20–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Wong VC, Lee AK, Ip HM. Transmission of hepatitis B antigens from symptom free carrier mothers to the fetus and the infant. Br J Obstet Gynaecol. 1980;87:958–65.CrossRefPubMedGoogle Scholar
  39. 39.
    Beasley RP, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, Wang KY, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology. 1983;3(2):135–41.CrossRefPubMedGoogle Scholar
  40. 40.
    Schalm SW, Mazel JA, de Gast GC, Heijtink RA, Botman MJ, Banffer JR, et al. Prevention of hepatitis B infection in newborns through mass screening and delayed vaccination of all infants of mothers with hepatitis B surface antigen. Pediatrics. 1989;83(6):1041–8.PubMedGoogle Scholar
  41. 41.
    Stevens CE, Toy PT, Tong MJ, Taylor PE, Vyas GN, Nair PV, et al. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA. 1985;253(12):1740–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Ko TM, Tseng LH, Chang MH, Chen DS, Hsieh FJ, Chuang SM, et al. Amniocentesis in mothers who are hepatitis B virus carriers does not expose the infant to an increased risk of hepatitis B virus infection. Arch Gynecol Obstet. 1994;255:25–30.CrossRefPubMedGoogle Scholar
  43. 43.
    Alexander JM, Ramus R, Jackson G, Sercely B, Wendel GD Jr. Risk of hepatitis B transmission after amniocentesis in chronic hepatitis B carriers. Infect Dis Obstet Gynecol. 1999;7:283–6.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Towers CV, Asrat T, Rumney P. The presence of hepatitis B surface antigen and deoxyribonucleic acid in amniotic fluid and cord blood. Am J Obstet Gynecol. 2001;184:1514–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Yi W, Pan CQ, Hao J, Hu Y, Liu M, Li L, Liang D. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. J Hepatol. 2014;60(3):523–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Dionne-Odom J, Tita AT, Silverman NS. # 38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol. 2016;214(1):6–14.CrossRefPubMedGoogle Scholar
  47. 47.
    Centers for Disease Control and Prevention (CDC). Global routine vaccination coverage—2012. Morb Mortal Wkly Rep. 2013;62:858–61.Google Scholar
  48. 48.
    Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis B immunoglobulin: double-blind randomised placebo-controlled study. Lancet. 1984;1(8383):921–6.CrossRefPubMedGoogle Scholar
  49. 49.
    Lo KJ, Tsai YT, Lee SD, Wu JC, Wu TC, Yang ZL, et al. Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan. Hepatogastroenterology. 1985;32(2):65–8.PubMedGoogle Scholar
  50. 50.
    Chen SC, Toy M, Yeh JM, Wang JD, Resch S. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment [erratum appears in Pediatrics 2014;133(2):346]. Pediatrics. 2013;131(4):e1135–43. doi: 10.1542/peds.2012-1262.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Lolekha S, Warachit B, Hirunyachote A, Bowonkiratikachorn P, West DJ, Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine. 2002;20(31–32):3739–43.CrossRefPubMedGoogle Scholar
  52. 52.
    Hu Y, Zhang S, Luo C, Liu Q, Zhou YH. Gaps in the prevention of perinatal transmission of hepatitis B virus between recommendations and routine practices in a highly endemic region: a provincial population-based study in China. BMC Infect Dis. 2012;12:221.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Huang Y, Li L, Sun X, Lu M, Liu H, Tang G, et al. Screening of pregnant women for hepatitis B virus surface antigen (HBsAg) and subsequent management, Qiandongnan prefecture, Guizhou, China, 2010. Vaccine. 2013;31(Suppl. 9):S62–5.CrossRefGoogle Scholar
  54. 54.
    Centers for Disease Control and Prevention (CDC). Hepatitis B vaccine birthdose practices in a country where hepatitis B is endemic—Laos, December 2011–February 2012. Morb Mortal Wkly Rep. 2013;62(29):587–90.Google Scholar
  55. 55.
    Wang J, Zhu Q, Zhang X. Effect delivery mode on maternal-infant transmission of hepatitis B virus by immunoprophylaxis. Chin Med J. 2002;115:1510–2.PubMedGoogle Scholar
  56. 56.
    Yang J, Zeng X, Men Y, Zhao L. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus—a systematic review. Virol J. 2008;5:100.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Zou H, Chen Y, Duan Z, Zhang H, Pan C. A retrospective study for clinical outcome of caesarean section on perinatal transmission of hepatitis B virus in infants born to HBeAg positive mothers with chronic hepatitis B (CHB). Hepatology. 2010;52(Suppl(1)):441A.Google Scholar
  58. 58.
    Pan CQ, Zou HB, Chen Y, Zhang X, Zhang H, Li J, Duan Z. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. Clin Gastroenterol Hepatol. 2013;11(10):1349–55.CrossRefPubMedGoogle Scholar
  59. 59.
    Luo ZB, Li LJ, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis. 2012;16:e82–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunization in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006;332:328–36.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003;10:294–7.CrossRefPubMedGoogle Scholar
  62. 62.
    Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16(2):94–103.CrossRefPubMedGoogle Scholar
  63. 63.
    Han L, Zhang H-W, Xie J-X, Zhang Q, Wang HY, Cao GW, et al. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol. 2011;17:4321–33.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55(6):1215–21.CrossRefPubMedGoogle Scholar
  65. 65.
    Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60(2):468–76.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Wu Q, Huang H, Sun X, Pan M, He Y, Tan S, et al. Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study. Clin Gastroenterol Hepatol. 2015;13(6):1170–6.CrossRefPubMedGoogle Scholar
  67. 67.
    Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, et al.; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT Study); Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV PreMIT Study. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015;62(2):375–86.Google Scholar
  68. 68.
    Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al.; China Study Group for the Mother-to-Child Transmission of Hepatitis B. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324–34.Google Scholar
  69. 69.
    Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61(3):502–7.CrossRefPubMedGoogle Scholar
  70. 70.
    Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load. Obstet Gynecol. 2014;123(5):929–37.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Hung HF, Chen HH. Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection. Pharmacoeconomics. 2011;29(12):1063–73.CrossRefPubMedGoogle Scholar
  72. 72.
    Wang W, Wang J, Dang S, Zhuang G. Cost-effectiveness of antiviral therapy during late pregnancy to prevent perinatal transmission of hepatitis B virus. PeerJ. 2016;24(4):e1709.CrossRefGoogle Scholar
  73. 73.
    Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol. 2002;99:1049–52.PubMedGoogle Scholar
  74. 74.
    Shi Z, Yang Y, Wang H, Ma L, Schreiber A, Li X, et al. Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. Arch Pediatr Adolesc Med. 2011;165(9):837–46.CrossRefPubMedGoogle Scholar
  75. 75.
    World Health Organization. Hepatitis B and breastfeeding. No. 22. Geneva: WHO; 1996. http://www.who.int/child_adolescent_health/documents/pdfs/hepatitis_b_and_breastfeeding.pdf. Accessed 27 Nov 2016.
  76. 76.
    Benaboud S, Pruvost A, Coffie PA, Ekouévi DK, Urien S, Arrivé E, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d’Ivoire, in the ANRS12109 TEmAA Study, step 2. Antimicrob Agents Chemother. 2011;55:1315–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of MedicinePrince of Songkla UniversitySongkhlaThailand
  2. 2.Department of Medicine, NKC Institute of Gastroenterology and HepatologyPrince of Songkla UniversityHat YaiThailand

Personalised recommendations